AstraZeneca Plc said it is discontinuing development of the monoclonal antibody, motavizumab, for the prevention of respiratory syncytial virus disease. But it will continue work on the antibody as a treatment for RSV, a respiratory tract infection.
AstraZeneca Plc said it is discontinuing development of the monoclonal antibody, motavizumab, for the prevention of respiratory syncytial virus disease. But it will continue work on the antibody as a treatment for RSV, a respiratory tract infection.